Abstract:Background The most common type of kidney cancer that easily metastasizes is clear cell renal cell carcinoma (ccRCC). The expression levels of hyaluronan-mediated motility receptor (HMMR) in many tumor types are significantly enhanced. HMMR is closely associated with tumor-related progression, treatment resistance, and discouraging prognosis, has yet to be fully investigated in terms of its expression patterns and molecular mechanisms of action in ccRCC. Further research is imperative to elucidate these aspects. Methods We used The Cancer Genome Atlas (TCGA) database to preliminarily investigate HMMR expression and function in ccRCC. We assessed the differential expression level of HMMR between ccRCC cancerous tissues and their matched non-tumor tissues. Subsequently, a series of in vivo and in vitro experiments were designed to elucidate the biological function of HMMR in ccRCC, including Transwell migration assays, CCK-8 assays, clone formation assays and subcutaneous xenograft experiments in nude mice. Through bioinformatics analysis, we identified potential microRNAs (miRNAs) that may regulate HMMR, as well as the possible signaling pathways involved. Finally, we conducted a series of cellular functional experiments to validate our hypotheses regarding the HMMR axis. Results HMMR expression was observably up-regulated in tumor tissues of ccRCC patients, and elevated HMMR expression level showed a strong correlation with ccRCC progression and adverse prognoses of patients. Knocking down HMMR inhibited the proliferative and migratory abilities of ccRCC cells, while its overexpression amplified these oncogenic properties. In nude mouse model, reduced HMMR expression inhibited ccRCC tumor proliferation in vivo. Furthermore, overexpression of an upstream transcriptional regulator, miR-9-5p, effectively downregulated HMMR expression and thus impeded ccRCC cells proliferation and migration. In addition, HMMR might influence ccRCC growth via the Epithelial-Mesenchymal Transition (EMT) pathway and the Janus Kinase1/Signal Transducer and Activator of Transcription1 (JAK1/STAT1) pathway. Conclusions HMMR is overexpressed in ccRCC, and there is a significant link between high HMMR expression and tumor progression, as well as poor patient prognosis. Specifically, HMMR could be targeted and inhibited by miR-9-5p and might modulate the tumorigenesis and progression of ccRCC through both EMT and JAK1/STAT1 signaling pathway.

Mortalin promotes breast cancer malignancy

Prognostic value of Mortalin correlates with roles in epithelial-mesenchymal transition and angiogenesis in lung adenocarcinoma

Mortalin promotes the evolution of androgen-independent prostate cancer through Wnt/β-catenin signaling pathway

Expression of mortalin detected in human liver cancer by tissue microarrays.

Mortalin maintains breast cancer stem cells stemness via activation of Wnt/GSK3β/β-catenin signaling pathway.

Mortalin Promotes Cell Proliferation and Epithelial Mesenchymal Transition of Intrahepatic Cholangiocarcinoma Cells in Vitro.

Oncogenic Role of Mortalin Contributes to Ovarian Tumorigenesis by Activating the MAPK–ERK Pathway

Mortalin Stabilizes CD151-depedent Tetraspanin-Enriched Microdomains and Implicates in the Progression of Hepatocellular Carcinoma.

Expression of Mortalin in Human Hepatoma-Derived Cell Lines and Its Role in Epithelial-Mesenchymal Transition

Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis.

Involvement and Targeted Intervention of Mortalin-Regulated Proteome Phosphorylated-Modification in Hepatocellular Carcinoma

MDK Protein Overexpression Correlates with the Malignant Status and Prognosis of Non-small Cell Lung Cancer

MNS1 Promotes Hepatocarcinogenesis and Metastasis Via Activating PI3K/AKT by Translocating Β‐catenin and Predicts Poor Prognosis

NF‐κB P65 Promotes Ovarian Cancer Cell Proliferation and Migration Via Regulating Mortalin

A Novel Mechanism of Lung Cancer Inhibition by Methionine Enkephalin Through Remodeling the Immune Status of the Tumor Microenvironment

Mir-9-5p/hmmr Regulates the Tumorigenesis and Progression of Clear Cell Renal Cell Carcinoma Through EMT and JAK1/STAT1 Signaling Pathway

Association of Mortalin (HSPA9) with Liver Cancer Metastasis and Prediction for Early Tumor Recurrence

Synthetic and Natural Inhibitors of Mortalin for Cancer Therapy

Inhibition of Mortalin Expression Reverses Cisplatin Resistance and Attenuates Growth of Ovarian Cancer Cells.

METTL3-mediated HSPA9 m6A modification promotes malignant transformation and inhibits cellular senescence by regulating exosomal mortalin protein in cervical cancer